Related references
Note: Only part of the references are listed.Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
Andrew J. Muir et al.
HEPATOLOGY (2019)
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Keith D. Lindor et al.
HEPATOLOGY (2019)
Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis
Akira Honda et al.
HEPATOLOGY (2019)
Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan
Atsushi Tanaka et al.
HEPATOLOGY RESEARCH (2019)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Michael Trauner et al.
HEPATOLOGY (2019)
Clinical features of pediatric autoimmune hepatitis in Japan: A nationwide survey
Tsuyoshi Sogo et al.
HEPATOLOGY RESEARCH (2018)
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy
Stuart K. Roberts et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis
Moritz Peiseler et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice
Maria Eugenia Guicciardi et al.
JOURNAL OF HEPATOLOGY (2018)
Primary sclerosing cholangitis
Jessica K. Dyson et al.
LANCET (2018)
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C. Corpechot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
Marco Carbone et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
NI-0801, an Anti-Chemokine (C-X-C Motif) Ligand 10 Antibody, in Patients With Primary Biliary Cholangitis and an Incomplete Response to Ursodeoxycholic Acid
Kathy L. de Graaf et al.
HEPATOLOGY COMMUNICATIONS (2018)
Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis
Marco Carbone et al.
HEPATOLOGY COMMUNICATIONS (2018)
Expert clinical management of autoimmune hepatitis in the real world
R. Liberal et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Long-Term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis
Sumeyye Samur et al.
HEPATOLOGY (2017)
Challenges and difficulties in pathological diagnosis of autoimmune hepatitis
Kenichi Harada et al.
HEPATOLOGY RESEARCH (2017)
No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan
Atsushi Tanaka et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2017)
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Gideon M. Hirschfield et al.
JOURNAL OF HEPATOLOGY (2017)
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Peter Fickert et al.
JOURNAL OF HEPATOLOGY (2017)
Primary sclerosing cholangitis - a comprehensive review
Tom H. Karlsen et al.
JOURNAL OF HEPATOLOGY (2017)
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study
Vinod S. Hegade et al.
LANCET (2017)
Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial
Ruth Bolier et al.
TRIALS (2017)
Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol
Katherine Arndtz et al.
BMJ OPEN (2017)
Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes
A. C. Cheung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Surrogate Endpoints for Clinical Trials in Primary Sclerosing Cholangitis: Review and Results From an International PSC Study Group Consensus Process
Cyriel Y. Ponsioen et al.
HEPATOLOGY (2016)
The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis
Marco Carbone et al.
HEPATOLOGY (2016)
Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score
Vinod S. Hegade et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Primary sclerosing cholangitis: 50 years of a gut-liver relationship and still no love?
Tom H. Karlsen
GUT (2016)
Ustekinumab for Patients With Primary Biliary Cholangitis Who Have an Inadequate Response to Ursodeoxycholic Acid: A Proof-of-Concept Study
Gideon M. Hirschfield et al.
HEPATOLOGY (2016)
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
F. Nevens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia
Kenichi Hosonuma et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy
Willem J. Lammers et al.
GASTROENTEROLOGY (2015)
Autoimmune Hepatitis: Recent Advances in the Pathogenesis and New Diagnostic Guidelines in Japan
Hiromasa Ohira et al.
INTERNAL MEDICINE (2015)
Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis
Suguru Mizuno et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2015)
Autoimmune hepatitis - Update 2015
Michael P. Manns et al.
JOURNAL OF HEPATOLOGY (2015)
EASL Clinical Practice Guidelines: Autoimmune hepatitis
JOURNAL OF HEPATOLOGY (2015)
Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA
Atsushi Tanaka et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study
Willem J. Lammers et al.
GASTROENTEROLOGY (2014)
Guidelines for the management of primary biliary cirrhosis
Atsumasa Komori et al.
HEPATOLOGY RESEARCH (2014)
B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid
Robert P. Myers et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid
Akira Honda et al.
HEPATOLOGY (2013)
Long-term outcome of Japanese patients with type 1 autoimmune hepatitis
Kaname Yoshizawa et al.
HEPATOLOGY (2012)
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Njideka Momah et al.
LIVER INTERNATIONAL (2012)
Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome
Christophe Corpechot et al.
JOURNAL OF HEPATOLOGY (2011)
Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients
Kalliopi Zachou et al.
JOURNAL OF HEPATOLOGY (2011)
Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment
Ansgar W. Lohse et al.
JOURNAL OF HEPATOLOGY (2011)
Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis
Teru Kumagi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy
Kaveh Sharzehi et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis
Michael P. Manns et al.
GASTROENTEROLOGY (2010)
Diagnosis and Management of Autoimmune Hepatitis
Michael P. Manns et al.
HEPATOLOGY (2010)
Mycophenolate Mofetil for Autoimmune Hepatitis: A Single Practice Experience
David C. Wolf et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
Edith M. M. Kuiper et al.
GASTROENTEROLOGY (2009)
Side Chain Structure Determines Unique Physiologic and Therapeutic Properties of norUrsodeoxycholic Acid in Mdr2-/- Mice
Emina Halilbasic et al.
HEPATOLOGY (2009)
Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis
Nobuaki Azemoto et al.
JOURNAL OF GASTROENTEROLOGY (2009)
Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?
Elke M. Hennes et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Simplified criteria for the diagnosis of autoimmune hepatitis
Elke M. Hennes et al.
HEPATOLOGY (2008)
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Christophe Corpechot et al.
HEPATOLOGY (2008)
The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study
Shinji Iwasaki et al.
HEPATOLOGY RESEARCH (2008)
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis
Keith Lindor
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid
A Parés et al.
GASTROENTEROLOGY (2006)
Empiric therapy of autoimmune hepatitis with mycophenolate mofetil - Comparison with conventional treatment for refractory disease
AJ Czaja et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis
RE Poupon et al.
JOURNAL OF HEPATOLOGY (2003)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis
C Corpechot et al.
HEPATOLOGY (2000)
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
P Angulo et al.
HEPATOLOGY (2000)
Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine
PD Richardson et al.
JOURNAL OF HEPATOLOGY (2000)
Share Paper
